Humacyte, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
HUMA$0.46+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 12th day of November, 2025.
| HUMACYTE, INC. | |||
| Date: November 12, 2025 | By: | /s/ Laura E. Niklason, M.D., Ph.D. | |
|---|---|---|---|
| Name: | Laura E. Niklason, M.D., Ph.D. | ||
| Title: | President and Chief Executive Officer | ||
| By: | /s/ Dale A. Sander | ||
| Name: | Dale A. Sander | ||
| Title: | Chief Financial Officer, Chief Corporate Development Officer and Treasurer | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.